A study identifying which biomarkers are predictive of a good clinical response following treatment with Xolair in patients with severe asthma
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 01 Mar 2018
At a glance
- Drugs Omalizumab (Primary)
- Indications Asthma
- Focus Biomarker; Pharmacodynamics
- Acronyms SoMOSA
- Sponsors Novartis
- 31 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 31 Jan 2018 Planned End Date changed from 30 Sep 2019 to 31 Aug 2019.
- 29 Jan 2018 Status changed from active, no longer recruiting to recruiting.